Immunotherapy, which uses programmed immune cells to selectively destroy cancer cells, has transformed cancer treatment.

Under the terms of the agreement, Novartis will pay $925 million upfront and up to $2.15 billion, contingent upon achievement ...

Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug ...

After an apparent accidental early release, Pfizer has revealed phase 1 data showing its investigational candidate, alongside ...

Jefferies analyst Akash Tewari increased the price target for Pfizer (NYSE:PFE) shares from $33.00 to $34.00, while ...

By Ludwig Burger and Ariane Luthi (Reuters) -Swiss pharmaceutical giant Novartis has agreed to acquire Anthos Therapeutics, a ...

A paper inadvertently published on the website of an ASCO conference revealed good results for mevrometostat in treating ...

In a systematic review and meta-analysis of trials of non-vitamin K oral anticoagulants vs. single antiplatelet therapy, ...

A private boarding school in rural western Massachusetts that opened in the 19th century is receiving a $50 million bequest ...

Hims & Hers' “Sick of the System” spot not only generated the highest engagement of all pharma-related ads that aired during ...

Pfizer (PFE) and Astellas Pharma announced additional follow-up results from the Phase 3 EV-302 clinical trial evaluating the efficacy and ...

On Friday, the U.S. Judicial Panel on Multidistrict Litigation ordered nearly 70 lawsuits be coordinated beefore U.S.